Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.37 |
| ▸ | ADH1A | P07327 | 4/20 | 0.35 |
| ▸ | ADH1C | P00326 | 3/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL923554 | 0.86 | EPHX1 (0.39) | EPHX1ADH1AADH1CHSD11B1GAA | |
| SCHEMBL8167342 | 0.84 | EPHX1 (0.37) | EPHX1ADH1AADH1CHDAC6HSD11B1 | |
| SCHEMBL4717930 | 0.84 | HDAC6 (0.33) | HDAC6DPP4 | |
| SCHEMBL15778145 | 0.83 | CNR2 (0.31) | HDAC6 | |
| SCHEMBL13494079 | 0.83 | ADH1A (0.41) | EPHX1ADH1AADH1CHSD11B1GAA | |
| SCHEMBL1067463 | 0.83 | EPHX1 (0.36) | EPHX1HSD11B1GAADPP4 | |
| SCHEMBL25736668 | 0.82 | EPHX1 (0.38) | EPHX1HDAC6HSD11B1GAA | |
| SCHEMBL10323856 | 0.81 | CA14 (0.34) | EPHX1HSD11B1GAADPP4 | |
| SCHEMBL27510109 | 0.81 | EPHX1 (0.39) | EPHX1HSD11B1GAADPP4 | |
| SCHEMBL9200042 | 0.81 | KDM5A (0.38) | EPHX1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1890703-B1 | PYRIMIDINE COMPOUNDS AS CHEMOKINE RECEPTORS INHIBITORS | TAIGEN BIOTECHNOLOGY CO LTD (TW) | 2016-05-11 | — | — | EP | disclosed |
| US-9023834-B2 | Lyophilization formulation | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2015-05-05 | — | — | US | disclosed |
| US-8372849-B2 | Heterocyclic compounds | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2013-02-12 | — | — | US | disclosed |
| US-8193206-B2 | Pyrimidine compounds | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2012-06-05 | — | — | US | disclosed |
| US-8193206-B2 | Pyrimidine compounds | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2012-06-05 | — | — | US | disclosed |
| EP-2195314-A1 | DISUBSTITUTED ALKYL-8-AZABICYCLO [3.2.1.]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2010-06-16 | — | — | EP | disclosed |
| US-20100120719-A1 | LYOPHILIZATION FORMULATION | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2010-05-13 | — | — | US | disclosed |
| US-20090264339-A1 | Heterocyclic Compounds | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-10-22 | — | — | US | disclosed |
| US-7589197-B2 | Pyrimidine compounds | TAIGEN BIOTECHNOLOGY (TW) | 2009-09-15 | — | — | US | disclosed |
| US-7589197-B2 | Pyrimidine compounds | TAIGEN BIOTECHNOLOGY (TW) | 2009-09-15 | — | — | US | disclosed |
| US-20090143302-A1 | PYRIMIDINE COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-06-04 | — | — | US | disclosed |
| US-20090143302-A1 | PYRIMIDINE COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-06-04 | — | — | US | disclosed |
| WO-2009029257-A1 | DISUBSTITUTED ALKYL-8-AZABICYCLO [3.2.1.] OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143302-A1 | PYRIMIDINE COMPOUNDS | TYMS, TYMP, HPRT1 | EPHX1 368/4885ADH1A 3388/4885ADH1C 3280/4885 |
| US-20100120719-A1 | LYOPHILIZATION FORMULATION | DPYD, TYMP, TYMS | EPHX1 2422/4885ADH1A 2765/4885ADH1C 2537/4885 |
| US-20090264339-A1 | Heterocyclic Compounds | AHR, NQO1, LTC4S | EPHX1 105/4885ADH1A 1495/4885ADH1C 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.